Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'

Box fighters trainning outdoor . Mixed media

Allergan PLC argued that its deal with the Saint Regis Mohawk Tribe would block generic drug makers from unfairly getting a second chance to eliminate its Restasis (cyclosporine) patents. But now that a judge has ruled the patents are invalid it may regret trying to derail the inter partes review (IPR) process, since the move may end up resulting only in harm to the firm's reputation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By 

Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.

India Digital Personal Data Protection Norms: What It May Mean For Clinical Trials, Big Pharma GCCs

 

Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.

Semaglutide In 2027 Medicare Price Negotiations; Most Other Drugs Lose Exclusivity By Then

 
• By 

Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.

Lens On Pharma Marketing ‘Ploys’ In India: Can The Genie Be Tamed?

 

India cracks down on unethical marketing practices, with AbbVie in the eye of a storm for allegedly violating norms. While the action sends the right signal, a wider clean up including in the devices segment, where things may be “more harmful” may not be easy, say some experts.

More from Business

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By 

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By 

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.